CA3055653A1 - Lipid nanoparticle formulation - Google Patents
Lipid nanoparticle formulation Download PDFInfo
- Publication number
- CA3055653A1 CA3055653A1 CA3055653A CA3055653A CA3055653A1 CA 3055653 A1 CA3055653 A1 CA 3055653A1 CA 3055653 A CA3055653 A CA 3055653A CA 3055653 A CA3055653 A CA 3055653A CA 3055653 A1 CA3055653 A1 CA 3055653A1
- Authority
- CA
- Canada
- Prior art keywords
- nanoparticle composition
- alkyl
- group
- lipid
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471949P | 2017-03-15 | 2017-03-15 | |
| US62/471,949 | 2017-03-15 | ||
| US201762475166P | 2017-03-22 | 2017-03-22 | |
| US62/475,166 | 2017-03-22 | ||
| PCT/US2018/022756 WO2018170336A1 (en) | 2017-03-15 | 2018-03-15 | Lipid nanoparticle formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3055653A1 true CA3055653A1 (en) | 2018-09-20 |
Family
ID=61874015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3055653A Pending CA3055653A1 (en) | 2017-03-15 | 2018-03-15 | Lipid nanoparticle formulation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11969506B2 (https=) |
| EP (1) | EP3595727B1 (https=) |
| JP (2) | JP7332478B2 (https=) |
| AU (1) | AU2018234828A1 (https=) |
| CA (1) | CA3055653A1 (https=) |
| ES (1) | ES3020935T3 (https=) |
| WO (1) | WO2018170336A1 (https=) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| WO2015195967A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MX382122B (es) | 2015-07-06 | 2025-03-13 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| PL3319611T3 (pl) | 2015-07-06 | 2021-07-12 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| AU2016289965B2 (en) | 2015-07-06 | 2021-09-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2017020026A1 (en) | 2015-07-30 | 2017-02-02 | Modernatx, Inc. | Concatemeric peptide epitopes rnas |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| EP3436022B1 (en) | 2016-04-01 | 2022-03-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| CN116837052A (zh) | 2016-09-14 | 2023-10-03 | 摩登纳特斯有限公司 | 高纯度rna组合物及其制备方法 |
| PT3519422T (pt) | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| DK4105223T3 (da) | 2016-10-18 | 2025-07-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| CA3041088C (en) | 2016-10-18 | 2024-05-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018187590A1 (en) | 2017-04-05 | 2018-10-11 | Modernatx, Inc. | Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| JP2021512090A (ja) * | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| AU2019345067A1 (en) * | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| JP7636330B2 (ja) * | 2019-01-17 | 2025-02-26 | ジョージア テック リサーチ コーポレイション | 酸化コレステロールを含有する薬物送達システム |
| MX2021009236A (es) | 2019-01-31 | 2021-11-12 | Modernatx Inc | Agitadores vorticiales y metodos, sistemas y aparatos asociados de estos. |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| EP3938379A4 (en) | 2019-03-15 | 2023-02-22 | ModernaTX, Inc. | Hiv rna vaccines |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| US20230285297A1 (en) | 2020-01-31 | 2023-09-14 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| CN111920957A (zh) * | 2020-08-04 | 2020-11-13 | 河南中医药大学 | 一种线粒体靶向生育酚-齐墩果酸双药纳米粒的制备方法 |
| KR20230167008A (ko) | 2020-08-06 | 2023-12-07 | 모더나티엑스, 인크. | 지질 나노입자의 제조 방법 |
| KR20230087443A (ko) * | 2020-08-06 | 2023-06-16 | 모더나티엑스, 인크. | 페이로드 분자를 기도 상피로 전달하기 위한 조성물 |
| JP2023546175A (ja) | 2020-10-14 | 2023-11-01 | ジョージ・メイソン・リサーチ・ファウンデーション・インコーポレイテッド | 脂質ナノ粒子製造の方法及びそれに由来する組成物 |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| KR102537540B1 (ko) * | 2020-12-24 | 2023-05-26 | (주)인핸스드바이오 | 만노스를 포함하는 지질 나노입자 또는 이의 용도 |
| US12329811B2 (en) | 2021-01-11 | 2025-06-17 | Modernatx, Inc. | Seasonal RNA influenza virus vaccines |
| JP2024506908A (ja) * | 2021-02-12 | 2024-02-15 | モデルナティエックス インコーポレイテッド | インビボ療法のためのペイロードを含むｌｎｐ組成物 |
| CN116867899A (zh) * | 2021-02-16 | 2023-10-10 | 英属哥伦比亚大学 | 用于调节纤溶酶原的方法和组合物 |
| US20240173431A1 (en) * | 2021-03-10 | 2024-05-30 | Oregon State University | Nanotherapeutics for treatment of sars-cov-2 |
| CN113402404B (zh) * | 2021-04-30 | 2022-03-11 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN115671294A (zh) * | 2021-07-27 | 2023-02-03 | 中国医学科学院基础医学研究所 | St类脂质化合物在制备核酸递送试剂中的应用及相关产品 |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| CA3233490A1 (en) * | 2021-09-28 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell targeted delivery of therapeutic agents |
| EP4408437A4 (en) * | 2021-10-01 | 2025-08-27 | Univ Pennsylvania | LIPID NANOPARTICLE (LNP) COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4429644A1 (en) * | 2021-11-12 | 2024-09-18 | ModernaTX, Inc. | Compositions for the delivery of payload molecules to airway epithelium |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250049728A1 (en) | 2021-12-16 | 2025-02-13 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| EP4691500A3 (en) * | 2022-03-15 | 2026-04-01 | FUJIFILM Corporation | Lipid composition |
| AU2023238223A1 (en) | 2022-03-23 | 2024-10-10 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
| WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
| CN119654166A (zh) | 2022-04-01 | 2025-03-18 | 内诺维什疗法股份有限公司 | mRNA递送方法及其组合物 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
| US20260097111A1 (en) * | 2022-10-19 | 2026-04-09 | Corner Therapeutics, Inc. | Ether lipids for hyperactivation of mammalian dendritic cells |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024094211A1 (zh) * | 2022-11-06 | 2024-05-10 | 斯微(上海)生物科技股份有限公司 | 一种脂质组合物 |
| WO2024107938A2 (en) * | 2022-11-17 | 2024-05-23 | The University Of North Carolina At Chapel Hill | Polyphenol lipid nanoparticles and methods of use |
| EP4628494A4 (en) * | 2022-12-06 | 2026-03-25 | Univ Beijing | PHOSPHATIDYLAMINE COMPOSITE COMPRISING MULTIPLE TERTIARY AMINO GROUP STRUCTURES, ASSOCIATED COMPOSITION AND USE |
| US20240226133A1 (en) * | 2023-01-09 | 2024-07-11 | Claudia Chimisso Dos Santos | Microrna-based particle for the treatment of dysregulated immune response |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| WO2024213098A1 (zh) * | 2023-04-14 | 2024-10-17 | 北京剂泰医药科技有限公司 | 靶向脾的脂质纳米颗粒 |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| US20250026713A1 (en) * | 2023-06-16 | 2025-01-23 | Beijing Jitai Pharmaceutical Technology Co., Ltd. | Rapidly metabolized lipid compound |
| WO2025137252A1 (en) * | 2023-12-20 | 2025-06-26 | Cz Biohub Sf, Llc | High throughput method for screening lipid nanoparticle efficacy and cytotoxicity |
| WO2025160381A1 (en) | 2024-01-26 | 2025-07-31 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026033498A1 (en) | 2024-08-09 | 2026-02-12 | Genvax Technologies, Inc. | Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom |
Family Cites Families (363)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3324182A (en) | 1962-12-26 | 1967-06-06 | Monsanto Res Corp | Penta-alkyldialkylenetriamines |
| US3872171A (en) | 1971-05-24 | 1975-03-18 | Pfizer | Polyamines as antiviral agents in animals |
| US4125544A (en) | 1977-06-09 | 1978-11-14 | G. D. Searle | 20/22/23/24-Oxa-7-oxocholesterols and esters thereof |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| ES2116269T3 (es) | 1989-03-21 | 1998-07-16 | Vical Inc | Expresion de secuencias exogenas de polinucleotidos en un vertebrado. |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| FR2676072B1 (fr) | 1991-05-03 | 1994-11-18 | Transgene Sa | Vecteur de delivrance d'arn. |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| WO1993014778A1 (en) | 1992-01-23 | 1993-08-05 | Vical, Inc. | Ex vivo gene transfer |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| US6673192B1 (en) | 1997-09-25 | 2004-01-06 | Loctite Corporation | Multi-amine compound primers for bonding of polyolefins with cyanoacrylate adhesives |
| AU1275899A (en) | 1997-10-24 | 1999-05-17 | Megabios Corporation | Methods for preparing polynucleotide transfection complexes |
| WO1999024595A1 (en) | 1997-11-12 | 1999-05-20 | The Brigham And Women's Hospital, Inc. | The translation enhancer element of the human amyloid precursor protein gene |
| DE69815707T2 (de) | 1997-11-20 | 2004-07-01 | Vical, Inc., San Diego | Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
| GB9808268D0 (en) | 1998-04-17 | 1998-06-17 | Imp College Innovations Ltd | Compound |
| US6395253B2 (en) | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| JP2000169864A (ja) | 1998-12-07 | 2000-06-20 | New Japan Chem Co Ltd | 模型エンジン用燃料組成物 |
| US8206749B1 (en) | 1999-02-26 | 2012-06-26 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| WO2001023002A1 (en) | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | Method for inhibition of pathogenic microorganisms |
| US7060291B1 (en) | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
| US7183395B2 (en) | 2000-01-28 | 2007-02-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US6696038B1 (en) | 2000-09-14 | 2004-02-24 | Expression Genetics, Inc. | Cationic lipopolymer as biocompatible gene delivery agent |
| US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10109897A1 (de) | 2001-02-21 | 2002-11-07 | Novosom Ag | Fakultativ kationische Liposomen und Verwendung dieser |
| CA2449054C (en) | 2001-05-30 | 2011-01-04 | The Scripps Research Institute | Integrin targeting liposome for nucleic acid delivery |
| ATE490267T1 (de) | 2001-06-05 | 2010-12-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt, kodierend für ein virales antigen |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| DE10207178A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Komponenten für die Herstellung amphoterer Liposomen |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US20050152980A1 (en) | 2002-03-13 | 2005-07-14 | Michael Ausborn | Pharmeutical microparticles |
| US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| EP1675614A2 (en) | 2003-10-11 | 2006-07-05 | Inex Pharmaceuticals Corp. | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| WO2005084180A2 (en) | 2003-12-19 | 2005-09-15 | University Of Cincinnati | Polyamides and polyamide complexes for delivery of oligonucleotide decoys |
| US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| KR101146160B1 (ko) | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| US8663599B1 (en) | 2004-10-05 | 2014-03-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| EP1856179B1 (en) | 2004-12-10 | 2013-05-15 | Kala Pharmaceuticals, Inc. | Functionalized poly (ether-anhydride) block copolymers |
| DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
| US9006487B2 (en) | 2005-06-15 | 2015-04-14 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| EP2479254A1 (en) | 2005-08-24 | 2012-07-25 | The Scripps Research Institute | Translation enhancer-element dependent vector systems |
| DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
| US8231907B2 (en) | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| EP2054036B1 (en) | 2006-07-24 | 2019-12-18 | Singh-Broemer and Company, Inc. | Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening |
| EP2049665A2 (en) | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
| EP3192788A1 (en) | 2006-10-03 | 2017-07-19 | Arbutus Biopharma Corporation | Lipid containing formulations |
| WO2008073558A2 (en) | 2006-10-05 | 2008-06-19 | The Johns Hopkins University | Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles |
| DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
| DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US7943168B2 (en) | 2007-03-05 | 2011-05-17 | Washington University | Nanoparticle delivery systems comprising a hydrophobic core and a lipid/surfactant layer comprising a membrane-lytic peptide |
| EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| WO2008127688A1 (en) | 2007-04-13 | 2008-10-23 | Hart Communication Foundation | Synchronizing timeslots in a wireless communication protocol |
| WO2008135855A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
| CA2686735A1 (en) | 2007-05-04 | 2008-11-13 | Mdrna, Inc. | Amino acid lipids and uses thereof |
| US20090042825A1 (en) | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| US9144546B2 (en) | 2007-08-06 | 2015-09-29 | Clsn Laboratories, Inc. | Nucleic acid-lipopolymer compositions |
| CA2695420A1 (en) | 2007-08-23 | 2009-02-26 | Novartis Ag | Methods for detecting oligonucleotides |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| TW200927915A (en) | 2007-10-25 | 2009-07-01 | Croda Int Plc | Laundry formulations and method of cleaning |
| WO2009075886A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2176408B9 (en) | 2008-01-31 | 2015-11-11 | Curevac GmbH | NUCLEIC ACIDS COMPRISING FORMULA (NuGiXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS |
| AU2009238175C1 (en) | 2008-04-15 | 2023-11-30 | Arbutus Biopharma Corporation | Novel lipid formulations for nucleic acid delivery |
| WO2009129395A1 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| WO2009129385A1 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic lipids and uses thereof |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| CA2722183C (en) | 2008-04-25 | 2018-09-18 | Northwestern University | Nanostructures suitable for sequestering cholesterol and other molecules |
| US8697098B2 (en) | 2011-02-25 | 2014-04-15 | South Dakota State University | Polymer conjugated protein micelles |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| WO2010005740A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| TW201019963A (en) | 2008-09-10 | 2010-06-01 | Abbott Lab | Polyethylene glycol lipid conjugates and uses thereof |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| ES2646630T3 (es) | 2008-11-07 | 2017-12-14 | Massachusetts Institute Of Technology | Lipidoides aminoalcohólicos y usos de los mismos |
| HUE037082T2 (hu) | 2008-11-10 | 2018-08-28 | Arbutus Biopharma Corp | Új lipidek és készítmények terápiás hatóanyagok szállítására |
| US8734853B2 (en) | 2008-11-17 | 2014-05-27 | University Of North Texas Health Science Center At Fort Worth | HDL particles for delivery of nucleic acids |
| WO2010060818A1 (de) | 2008-11-25 | 2010-06-03 | Basf Se | Alkoxylierte oligo- oder polyamine als oxidationsstabilisatoren |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
| US20140141089A1 (en) | 2009-02-11 | 2014-05-22 | Colorado School Of Mines | Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same |
| PT2414322T (pt) | 2009-03-20 | 2022-12-07 | Egen Inc | Derivados de poliamina |
| US8715736B2 (en) | 2009-04-30 | 2014-05-06 | Florida Agricultural And Mechanical University | Nanoparticle formulations for skin delivery |
| WO2010127159A2 (en) | 2009-04-30 | 2010-11-04 | Intezyne Technologies, Incorporated | Polymeric micelles for polynucleotide encapsulation |
| KR20180094137A (ko) | 2009-05-05 | 2018-08-22 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
| JP5889783B2 (ja) | 2009-05-05 | 2016-03-22 | テクミラ ファーマシューティカルズ コーポレイションＴｅｋｍｉｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ | 免疫細胞へオリゴヌクレオチドを送達する方法 |
| WO2010135207A1 (en) * | 2009-05-16 | 2010-11-25 | Agave Pharma, Incorporated | Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| NZ597504A (en) | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011017548A1 (en) | 2009-08-05 | 2011-02-10 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| US8449916B1 (en) | 2009-11-06 | 2013-05-28 | Iowa State University Research Foundation, Inc. | Antimicrobial compositions and methods |
| PH12012500929A1 (en) | 2009-11-12 | 2012-11-26 | Kao Corp | Method for producing olefins |
| HUE042177T2 (hu) | 2009-12-01 | 2019-06-28 | Translate Bio Inc | Szteroidszármazék mRNS szállítására humán genetikai betegségekben |
| WO2011071860A2 (en) | 2009-12-07 | 2011-06-16 | Alnylam Pharmaceuticals, Inc. | Compositions for nucleic acid delivery |
| WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
| US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
| CA2784568A1 (en) | 2009-12-18 | 2011-06-23 | The University Of British Columbia | Lipid particles for delivery of nucleic acids |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| EP2558074B1 (en) | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| CN104959087B (zh) | 2010-04-09 | 2017-08-15 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| JP5902616B2 (ja) | 2010-04-28 | 2016-04-13 | 協和発酵キリン株式会社 | カチオン性脂質 |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US9254327B2 (en) | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| US8748667B2 (en) | 2010-06-04 | 2014-06-10 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| CN103079592B (zh) | 2010-07-01 | 2015-10-21 | 浦项工科大学校产学协力团 | 使用来自细胞的微泡治疗和诊断癌症的方法 |
| HUE026646T2 (en) | 2010-07-06 | 2016-07-28 | Glaxosmithkline Biologicals Sa | Preferred liposomes containing lipids of PKA value for delivery of RNA |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| WO2012024595A2 (en) | 2010-08-20 | 2012-02-23 | University Of Washington | Circumferential aerosol device for delivering drugs to olfactory epithelium and brain |
| ES2727583T3 (es) | 2010-08-31 | 2019-10-17 | Glaxosmithkline Biologicals Sa | Lípidos adecuados para la administración liposómica de ARN que codifica proteínas |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| PT3970742T (pt) | 2010-08-31 | 2022-06-27 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para entrega de arn codificador de imunogénio |
| US9549901B2 (en) | 2010-09-03 | 2017-01-24 | The Brigham And Women's Hospital, Inc. | Lipid-polymer hybrid particles |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| ES2888231T3 (es) | 2010-09-20 | 2022-01-03 | Sirna Therapeutics Inc | Lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| EP2621480B1 (en) | 2010-09-30 | 2018-08-15 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| JP2013545727A (ja) | 2010-10-21 | 2013-12-26 | メルク・シャープ・アンド・ドーム・コーポレーション | オリゴヌクレオチド送達用の新規低分子量カチオン性脂質 |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| CN102068701B (zh) | 2011-01-18 | 2012-11-07 | 沈阳药科大学 | 可断裂peg脂质衍生物在制剂中的应用 |
| CA2825023A1 (en) | 2011-01-26 | 2012-08-02 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
| US10363309B2 (en) | 2011-02-04 | 2019-07-30 | Case Western Reserve University | Targeted nanoparticle conjugates |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| EP2675918B1 (en) | 2011-02-15 | 2017-11-08 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| CN102204920B (zh) | 2011-03-18 | 2013-03-20 | 海南本创医药科技有限公司 | 阿司匹林钠普伐他汀钠药物组合物固体制剂 |
| WO2012129483A1 (en) | 2011-03-24 | 2012-09-27 | Novartis Ag | Adjuvant nanoemulsions with phospholipids |
| KR101085203B1 (ko) | 2011-04-01 | 2011-11-21 | 서울대학교산학협력단 | 의약 전달용 인지질 나노입자 |
| WO2012142132A1 (en) | 2011-04-11 | 2012-10-18 | Life Technologies Corporation | Polymer particles and methods of making and using same |
| WO2013158127A1 (en) | 2012-04-16 | 2013-10-24 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
| AU2012249474A1 (en) | 2011-04-28 | 2013-11-07 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| ES2762224T3 (es) | 2011-05-12 | 2020-05-22 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Liposomas que comprenden lípidos conjugados con polímero y usos relacionados |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| CN103857387B (zh) | 2011-06-02 | 2017-03-15 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
| PL3586861T3 (pl) | 2011-06-08 | 2022-05-23 | Translate Bio, Inc. | Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna |
| EP3354644A1 (en) | 2011-06-08 | 2018-08-01 | Translate Bio, Inc. | Cleavable lipids |
| CN102813929B (zh) | 2011-06-09 | 2014-04-09 | 沈阳药科大学 | 低浓度peg脂质衍生物及其应用 |
| US20140141070A1 (en) | 2011-07-06 | 2014-05-22 | Andrew Geall | Liposomes having useful n:p ratio for delivery of rna molecules |
| CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| US11058762B2 (en) | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| SG10201605512WA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Oil-in-water emulsions that contain nucleic acids |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| CA2845845A1 (en) | 2011-08-31 | 2013-03-07 | Mallinckrodt Llc | Nanoparticle peg modification with h-phosphonates |
| EP3508220A1 (en) | 2011-08-31 | 2019-07-10 | GlaxoSmithKline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding rna |
| HRP20230747T1 (hr) | 2011-09-08 | 2024-01-05 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihova uporaba |
| WO2013072929A2 (en) | 2011-09-23 | 2013-05-23 | Indian Institute Of Technology | Nanop article based cosmetic composition |
| EP2760477B1 (en) | 2011-09-27 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| JP2014532071A (ja) | 2011-10-14 | 2014-12-04 | エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ | カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法 |
| JP6294229B2 (ja) | 2011-10-18 | 2018-03-14 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アミン陽イオン性脂質およびその使用 |
| CA2852857A1 (en) | 2011-10-20 | 2013-04-25 | Novartis Ag | Adjuvanted influenza b virus vaccines for pediatric priming |
| EP3069785A1 (en) | 2011-10-25 | 2016-09-21 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| WO2013066903A1 (en) | 2011-10-31 | 2013-05-10 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
| CA2853685C (en) | 2011-11-04 | 2019-09-03 | Nitto Denko Corporation | Single use system for sterilely producing lipid-nucleic acid particles |
| US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| WO2013067537A1 (en) | 2011-11-04 | 2013-05-10 | Univertiy Of Notre Dame Du Lac | Nanoparticle-based drug delivery |
| WO2013070872A1 (en) | 2011-11-08 | 2013-05-16 | The Board Of Trustees Of The University Of Arkansas | Methods and compositions for x-ray induced release from ph sensitive liposomes |
| BR112014013175B1 (pt) | 2011-12-02 | 2022-08-09 | Pegasus Laboratories, Inc | Processo para preparar comprimidos de composição de liberação prolongada |
| EP2788006B1 (en) | 2011-12-07 | 2026-01-07 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| EP2788316B1 (en) | 2011-12-07 | 2019-04-24 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013086526A1 (en) | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Liposomal drug encapsulation |
| CA2858694A1 (en) | 2011-12-12 | 2013-06-20 | Kyowa Hakko Kirin Co., Ltd. | Lipid nano particles comprising combination of cationic lipids |
| TWI594767B (zh) | 2011-12-12 | 2017-08-11 | 協和醱酵麒麟有限公司 | 含有陽離子性脂質之藥物傳遞系統用脂質奈米粒子 |
| EP2604253A1 (en) | 2011-12-13 | 2013-06-19 | Otto Glatter | Water-in-oil emulsions and methods for their preparation |
| WO2013087083A1 (en) | 2011-12-15 | 2013-06-20 | Biontech Ag | Particles comprising single stranded rna and double stranded rna for immunomodulation |
| CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| KR102081560B1 (ko) | 2012-02-09 | 2020-02-25 | 라이프 테크놀로지스 코포레이션 | 친수성 중합체성 입자 및 그의 제조 방법 |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| US20140037573A1 (en) | 2012-02-22 | 2014-02-06 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| US20130243867A1 (en) | 2012-02-23 | 2013-09-19 | University Of South Florida (A Florida Non-Profit Corporation) | Micelle compositions and methods for their use |
| SG11201405157PA (en) | 2012-02-24 | 2014-10-30 | Protiva Biotherapeutics Inc | Trialkyl cationic lipids and methods of use thereof |
| US10322089B2 (en) | 2012-03-14 | 2019-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Nanoparticles, nanoparticle delivery methods, and systems of delivery |
| NZ631034A (en) | 2012-03-16 | 2016-06-24 | Merck Patent Gmbh | Targeting aminoacid lipids |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2013148186A1 (en) | 2012-03-26 | 2013-10-03 | President And Fellows Of Harvard College | Lipid-coated nucleic acid nanostructures of defined shape |
| SG10201607962RA (en) | 2012-03-27 | 2016-11-29 | Curevac Ag | Artificial nucleic acid molecules |
| RU2658490C2 (ru) | 2012-03-27 | 2018-06-21 | Кьюрвак Аг | Искусственные молекулы нуклеиновых кислот для улучшенной экспрессии белков или пептидов |
| WO2013148541A1 (en) | 2012-03-27 | 2013-10-03 | Merck Sharp & Dohme Corp. | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY |
| WO2013143700A2 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| HK1206644A1 (en) | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| US20150064115A1 (en) | 2012-04-05 | 2015-03-05 | University Of Florida Research Foundation, Inc. | Neurophilic nanoparticles |
| US9603800B2 (en) | 2012-04-12 | 2017-03-28 | Yale University | Methods of treating inflammatory and autoimmune diseases and disorders using nanolipogels |
| AU2013249548A1 (en) | 2012-04-19 | 2014-11-06 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| WO2013163234A1 (en) | 2012-04-23 | 2013-10-31 | Massachusetts Institute Of Technology | Stable layer-by-layer coated particles |
| AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| WO2013173693A1 (en) | 2012-05-18 | 2013-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nanoparticles with enhanced entry into cancer cells |
| US9750819B2 (en) | 2012-05-23 | 2017-09-05 | Ohio State Innovation Foundation | Lipid nanoparticle compositions and methods of making and methods of using the same |
| WO2013174409A1 (en) | 2012-05-25 | 2013-11-28 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| SI2858974T1 (sl) | 2012-06-08 | 2019-01-31 | Nitto Denko Corporation | Lipidi za formulacije za dostavo terapevtskega sredstva |
| US10245229B2 (en) | 2012-06-08 | 2019-04-02 | Translate Bio, Inc. | Pulmonary delivery of mRNA to non-lung target cells |
| WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| TW201726600A (zh) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | 陽離子性脂質 |
| US9956291B2 (en) | 2012-07-10 | 2018-05-01 | Shaker A. Mousa | Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting |
| EP2882706A1 (en) | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
| WO2014026284A1 (en) | 2012-08-14 | 2014-02-20 | Froese Aaron | Internal structured self assembling liposomes |
| AU2013302526B2 (en) | 2012-08-15 | 2018-03-22 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
| WO2014047649A1 (en) | 2012-09-24 | 2014-03-27 | The Regents Of The University Of California | Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy |
| CA2925687A1 (en) | 2012-09-27 | 2014-04-03 | The University Of North Carolina At Chapel Hill | Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof |
| US20150202153A1 (en) | 2012-10-04 | 2015-07-23 | University Of The Witwatersrand, Johannesburg | Liposomal drug delivery system |
| WO2014071072A2 (en) | 2012-11-02 | 2014-05-08 | Pungente Michael D | Novel cationic carotenoid-based lipids for cellular nucleic acid uptake |
| US9669104B2 (en) | 2012-11-07 | 2017-06-06 | Council Of Scientific And Industrial Research | Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules |
| EP4331620A3 (en) | 2012-12-07 | 2024-12-04 | Translate Bio, Inc. | Lipidic nanoparticles for mrna delivery |
| RU2718988C2 (ru) | 2013-02-22 | 2020-04-15 | Куревак Аг | Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение |
| WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
| CA2906732C (en) * | 2013-03-15 | 2023-08-08 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| US10130649B2 (en) | 2013-03-15 | 2018-11-20 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
| US9895443B2 (en) | 2013-06-26 | 2018-02-20 | Massachusetts Institute Of Technology | Multi-tailed lipids and uses thereof |
| WO2015002667A1 (en) | 2013-07-01 | 2015-01-08 | Myq, Inc. | A location regulated point-of-sale system and enhancements |
| WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| SG11201510747RA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| WO2015024664A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Composition and vaccine for treating prostate cancer |
| DK3035955T3 (da) | 2013-08-21 | 2019-12-02 | Curevac Ag | Sammensætning og vaccine til behandling af lungekræft |
| ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
| US9365610B2 (en) | 2013-11-18 | 2016-06-14 | Arcturus Therapeutics, Inc. | Asymmetric ionizable cationic lipid for RNA delivery |
| EP4019506A1 (en) | 2013-12-19 | 2022-06-29 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| KR102399799B1 (ko) | 2013-12-30 | 2022-05-18 | 큐어백 아게 | 인공 핵산 분자 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| SG11201604198YA (en) | 2013-12-30 | 2016-07-28 | Curevac Ag | Methods for rna analysis |
| US10821175B2 (en) * | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| US9833416B2 (en) | 2014-04-04 | 2017-12-05 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| CN104644555A (zh) | 2014-11-18 | 2015-05-27 | 中国科学院过程工程研究所 | 一种避免加速血液清除现象的长循环脂质体、制备方法及应用 |
| US20180000953A1 (en) | 2015-01-21 | 2018-01-04 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
| LT3313829T (lt) | 2015-06-29 | 2024-08-12 | Acuitas Therapeutics Inc. | Lipidai ir lipidų nanodalelių sudėtys, skirtos nukleorūgščių tiekimui |
| EP3325505B1 (en) | 2015-07-23 | 2020-08-19 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| US20180289792A1 (en) | 2015-10-22 | 2018-10-11 | ModernaTX. Inc. | Sexually transmitted disease vaccines |
| TW201729835A (zh) | 2015-10-22 | 2017-09-01 | 現代公司 | 呼吸道病毒疫苗 |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| WO2017100744A1 (en) | 2015-12-11 | 2017-06-15 | Preceres Inc. | Aminolipidoids and uses thereof |
| MA43568A (fr) | 2015-12-17 | 2018-11-14 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| EP3397613A1 (en) | 2015-12-30 | 2018-11-07 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP3405579A1 (en) * | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2017176974A1 (en) | 2016-04-06 | 2017-10-12 | Ohio State Innovation Foundation | Biodegradable amino-ester nanomaterials for nucleic acid delivery |
| US20190167811A1 (en) | 2016-04-13 | 2019-06-06 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
| WO2017192470A1 (en) | 2016-05-03 | 2017-11-09 | Merck Sharp & Dohme Corp. | Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| AU2017266932B2 (en) | 2016-05-18 | 2023-04-20 | Modernatx, Inc. | Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
| WO2017201317A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
| EP3458106A4 (en) | 2016-05-18 | 2020-03-18 | Modernatx, Inc. | POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA |
| KR20230074598A (ko) * | 2016-05-18 | 2023-05-30 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| EP3458104A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
| KR102469450B1 (ko) | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| WO2017201347A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| EP3458474B1 (en) | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| WO2017201348A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
| WO2017218704A1 (en) * | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| BR112019008481A2 (pt) | 2016-10-26 | 2020-03-03 | Curevac Ag | Vacinas de mrna de nanopartículas lipídicas |
| ES3063077T3 (en) | 2016-10-26 | 2026-04-15 | Acuitas Therapeutics Inc | Lipid nanoparticle formulations |
| WO2018081638A1 (en) | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| WO2018200943A1 (en) | 2017-04-28 | 2018-11-01 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2018225871A1 (ja) | 2017-06-09 | 2018-12-13 | 協和発酵キリン株式会社 | カチオン性脂質としての化合物 |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| TW202039534A (zh) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | KRAS變體mRNA分子 |
| WO2021055849A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| BR112022004936A2 (pt) | 2019-09-19 | 2022-06-14 | Modernatx Inc | Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos |
| JP7681617B2 (ja) | 2020-04-09 | 2025-05-22 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質ナノ粒子組成物 |
| EP4313938A1 (en) | 2021-03-24 | 2024-02-07 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
-
2018
- 2018-03-15 US US16/493,814 patent/US11969506B2/en active Active
- 2018-03-15 ES ES18715417T patent/ES3020935T3/es active Active
- 2018-03-15 CA CA3055653A patent/CA3055653A1/en active Pending
- 2018-03-15 AU AU2018234828A patent/AU2018234828A1/en not_active Abandoned
- 2018-03-15 WO PCT/US2018/022756 patent/WO2018170336A1/en not_active Ceased
- 2018-03-15 EP EP18715417.4A patent/EP3595727B1/en active Active
- 2018-03-15 JP JP2019550770A patent/JP7332478B2/ja active Active
-
2023
- 2023-06-02 JP JP2023091299A patent/JP2023123477A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7332478B2 (ja) | 2023-08-23 |
| AU2018234828A1 (en) | 2019-09-19 |
| US11969506B2 (en) | 2024-04-30 |
| EP3595727B1 (en) | 2024-11-27 |
| JP2023123477A (ja) | 2023-09-05 |
| US20200129445A1 (en) | 2020-04-30 |
| JP2020510072A (ja) | 2020-04-02 |
| EP3595727A1 (en) | 2020-01-22 |
| ES3020935T3 (en) | 2025-05-23 |
| WO2018170336A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3595727B1 (en) | Lipid nanoparticle formulation | |
| US12144895B2 (en) | Stabilized formulations of lipid nanoparticles | |
| US12357575B2 (en) | Methods of making lipid nanoparticles | |
| US12151995B2 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| US12090235B2 (en) | Preparation of lipid nanoparticles and methods of administration thereof | |
| CA3128215A1 (en) | Methods of preparing lipid nanoparticles | |
| CA3056132A1 (en) | Compounds and compositions for intracellular delivery of therapeutic agents | |
| CA3007297A1 (en) | Compounds and compositions for intracellular delivery of agents | |
| CA3027201A1 (en) | Stabilized formulations of lipid nanoparticles | |
| HK40078722A (en) | Compounds and compositions for intracellular delivery of agents | |
| HK40039825A (en) | Compounds and compositions for intracellular delivery of therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230314 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240909 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |